Navigation Links
Latest Laser Fat Removal Procedure Now Available
Date:7/14/2008

Plastic Surgery Services of Fredericksburg is First in Virginia to Offer

Smartlipo MPX(TM)

FREDERICKSBURG, Va., July 14 /PRNewswire/ -- A laser-assisted procedure that kills fat cells and tightens skin is now being offered at Plastic Surgery Services of Fredericksburg.

The doctors' practice is the only one in Virginia to offer Smartlipo MPX(TM), a minimally invasive procedure that uses a high-power laser to eliminate fat cells in areas such as under the chin, neck or jaw line or in the abdomen, arms, thighs and knees.

"This is brand-new technology," said Lesi Beamon Mackey, PSSF office administrator. "This procedure offers more flexibility, more versatility and greater safety," than traditional laser lipolysis, she said.

The FDA-approved treatment uses a paperclip-thin cannula (or tube) that is inserted into the skin. Two lasers inside the tube send wavelengths of energy to fat cells, causing them to drain away. This also results in tighter skin, and less bruising and swelling than other techniques.

The procedure is designed for areas that don't respond to diet or exercise. It works best in small areas of the neck, jaw, arms, abdomen, inner and outer thighs and knees. The ideal candidate is in good health and of normal body weight.

Laser lipolysis has been available for a few years, Mackey said. She said PSSF surgeons wanted to make sure the procedure met doctor and patient expectations before offering it. Our doctors are very careful regarding trends in medical procedures."

She said enhanced safety features and skin tightening results convinced the doctors to offer this procedure.

Smartlipo MPX(TM) is less extensive than traditional liposuction and involves a shorter recovery period. The procedure can be performed in the doctor's office with local anesthesia. Patients can return to normal activities in a couple of days and resume strenuous exercise after two weeks recovery.
'/>"/>

SOURCE Plastic Surgery Services of Fredericksburg
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
2. Scientists, physicians present latest findings in personalized cancer treatment and prevention
3. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
4. Health psychologists discuss latest research findings
5. AIDS Action Council Praises Release of Latest State of AIDS in Black America Report
6. PA Governor Rendell Announces Latest Nominations and Appointments
7. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
8. Big Tobaccos Latest Dirty Trick: Deceiving Oregon Voters
9. Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side
10. The latest about male infertility and testosterone from NewYork-Presbyterian/Weill Cornell
11. Cejka Search Experts Present Latest Developments in Physician and Healthcare Employment at Leading Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...und by purchasing the Green Bracelet at www.simmon...wire/ -- The Diamond Empowerment Fund (D.E.F.), He...together to host the exclusive "Empowerment for Af...day evening in recognition of World AIDS Day. D.E.... including Tamsin Smith , President of the (RED) ...
(Date:12/4/2008)...anuary issue of European Urology , the official j...ished by Elsevier, will feature new recommendation...lated by major scientific organizations. LOH is a ...advancing age and characterized by typical symptom..., Late-onset hypogonadism (LOH) is caused by a d...
(Date:12/4/2008)...o are exposed to environmental tobacco smoke have ...ssion and other behavioral problems, according to ...cal Center. , In a study posted online ahead of ...ral Pediatrics , the researchers said behavioral p..., but they added even low levels of tobacco smoke ...
(Date:12/4/2008)...irstCall/ -- Transgenomic,(OTC Bulletin Board: TB...r,Research of Houston, Texas through its technolo...dation, has granted the Company an exclusive licen... DNA (mtDNA) damage detection.,The patents form t...n,cardiovascular disease, diabetes, degenerative ...
Breaking Medicine News(10 mins):Health News:On World AIDS Day, Russell Simmons and Special Guests Attended 'Empowerment for Africa' Dinner 2Health News:New recommendations by scientific societies about late-onset hypogonadism 2Health News:Study strengthens link between tobacco smoke and behavioral problems in boys with asthma 2Health News:Study strengthens link between tobacco smoke and behavioral problems in boys with asthma 3Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 2Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 3Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 4Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 5Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 6
...eorgia have found that, although a vacuum device p...'s cup size, few women may have the time and commi... BRAVA system, requires women to wear two plastic ...0 weeks straight.// The domes are connected to a b...
...e likely for Cesarean delivery, says Dr.Bell from ... one of the major causes of maternal mortality. //...eathe under general anesthesia, so a woman's risk ...ombined. Bell and colleagues studied more than 300...
...mounts of water is very essential for an individua...es of water a day, says a leading physiologist. We... two litres of water a day that's eight glasses//...ater balance expert Dr Heinz Valtin of Dartmouth M...
...researchers of University of Houston, a new study ... patients is associated with manageable side effec...to neuropathy.They examined the effects of escalat...Patients received oral thalidomide starting at 200...
Other Medicine News:Health News:Vacuum device increase breasts 2
(Date:12/3/2008)...E PLAINS, N.Y., Dec. 3 The Leukemi...ntly announce the beginning of a new clinical tria...f California, San Diego (UCSD). , , LLS ...t will speed the development and approval of a nov...abine refractory and/or 17p deleted chronic lympho...
(Date:12/3/2008)...DIEGO, Dec. 3 Vical Inco...lusive, binding letter of intent with EIP,Eczacib...ing of the company,s,Allovectin-7(R) immunotherap...,Republic of Northern Cyprus. EIP has agreed to ob...erritory and to pay Vical upfront and milestone pa...
(Date:12/2/2008)...OLLA, Calif., Dec. 2 TorreyPines T...d positive results from a 26 patient Phase II tria...for xerostomia, or dry mouth, in patients with Sjo...of a statistically significant increase in salivar... doses: 10 mg, 15 mg, and 20 mg. These doses were ...
(Date:12/1/2008)...VILLE, Md., Dec. 1 Vanda...blication in The Lancet , one of the world,s lead...f its novel circadian regulator, experimental comp...jaratnam et al(1) is entitled "Melatonin agonist t...sleep-time shift: two randomised controlled multic...
Breaking Medicine Technology:The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial 2The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 1Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 2Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 3Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4416 4Cardiac Science Corporation Schedules Third Quarter Earnings Release and Announces Conference Call 4412 1Cardiac Science Corporation Schedules Third Quarter Earnings Release and Announces Conference Call 4412 2CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007 1448 1CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007 1448 2CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007 1448 3PPD Reports Third Quarter 2007 Financial Results 3B Announces Increase in Annual Cash Dividend From 240 12 to 240 40 Per Year 1444 1PPD Reports Third Quarter 2007 Financial Results 3B Announces Increase in Annual Cash Dividend From 240 12 to 240 40 Per Year 1444 2PPD Reports Third Quarter 2007 Financial Results 3B Announces Increase in Annual Cash Dividend From 240 12 to 240 40 Per Year 1444 3PPD Reports Third Quarter 2007 Financial Results 3B Announces Increase in Annual Cash Dividend From 240 12 to 240 40 Per Year 1444 4PPD Reports Third Quarter 2007 Financial Results 3B Announces Increase in Annual Cash Dividend From 240 12 to 240 40 Per Year 1444 5PPD Reports Third Quarter 2007 Financial Results 3B Announces Increase in Annual Cash Dividend From 240 12 to 240 40 Per Year 1444 6
...Pluristem Life Systems,Inc. (OTCBB:PLRS), a cell ... of products for a variety of indications,announc...rs at the,13th Annual Meeting of the International...2007 in Sydney Australia., Pluristem CEO and Chair... more attention from the scientific community as o...
...ogen Idec (NASDAQ: BIIB),and Elan Corporation, plc...e TOUCH Prescribing Program(TM) and TYGRIS safety ...nical studies of,TYSABRI(R) (natalizumab). Also pr... Academy of Neurology in Boston, MA were extension...ed treatment,effect on clinical relapses and the r...
Other Medicine Technology:Pluristem to Present Two Scientific Posters at the International,Society for Cellular Therapy 2Pluristem to Present Two Scientific Posters at the International,Society for Cellular Therapy 3Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 2Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 3Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 4Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 5Data Presented at the American Academy of Neurology's Annual,Meeting Provide Update on Utilization and Safety of Tysabri in,Patients with Multiple Sclerosis 6
Basic ergonomic chairs with concave seats and standard-sized backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • BTP/1Q-PAL chairs are
Basic ergonomic chairs with concave seats and standard-sized backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • BTP/1Q-PAL chairs are
Basic ergonomic chairs with concave seats and standard-sized backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • BTN/1Q-CAB chairs are
Basic ergonomic chairs with concave seats and standard-sized backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • BTN/1Q-CAB chairs are
Medicine Products: